Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company whose news flow centers on the treatment and prevention of cancer. Company announcements frequently highlight progress in its ovarian cancer immunotherapy program and its portfolio of cancer vaccines, especially an investigational breast cancer vaccine developed in collaboration with Cleveland Clinic.
News items for ANIX often cover clinical trial milestones, such as completion of a Phase 1 trial, presentation of final data at major scientific meetings, and plans to advance programs into subsequent phases of development. For the breast cancer vaccine targeting α-lactalbumin, disclosures have included safety and immune response findings, details on trial cohorts, and steps to transfer the related IND sponsorship from Cleveland Clinic to Anixa for future trials.
Another recurring theme in Anixa’s news is its ovarian cancer CER-T (CAR-T) program, including regulatory and naming milestones. The company has reported that the World Health Organization’s International Nonproprietary Names Expert Committee approved “liraltagene autoleucel” (lira-cel) as the non-proprietary name for its FSHR-targeted CAR-T therapy, and updates often describe the ongoing first-in-human trial in recurrent ovarian cancer.
Investors and observers can also expect intellectual property updates, such as U.S. and international patent issuances that extend protection for the breast cancer vaccine technology, as well as participation in investor conferences and research-focused fireside chats. Together, these news items provide insight into Anixa’s clinical progress, collaboration activities with institutions like Cleveland Clinic and Moffitt Cancer Center, and the evolution of its immuno-oncology pipeline.
Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Pamela D. Garzone will present a poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30 to June 3, 2025. The presentation will focus on the company's Phase 1 clinical trial of their ovarian cancer CAR-T immunotherapy.
The poster, led by Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center and principal investigator of the trial, will discuss the study of autologous T-cells genetically engineered to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer. The presentation is scheduled for June 2, 2025, from 1:30 PM to 4:30 PM CT.
Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced its participation in the upcoming H.C. Wainwright 3rd Annual BioConnect Investor Conference.
The conference will take place on May 20, 2025, at the Nasdaq World Headquarters in New York City. Mike Catelani, who serves as President and CFO of Anixa, will deliver a presentation at 11:00 AM ET and will be available for one-on-one meetings throughout the conference.
Interested parties can access the presentation through a webcast link provided by the company. This investor conference appearance represents an opportunity for Anixa to showcase its developments in cancer-focused biotechnology to the investment community.
Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the USPTO for a new patent application covering its chimeric antigen receptor-T cell (CAR-T) technology. The allowed claims encompass core methods and compositions fundamental to Anixa's innovative CAR-T approach, which is specifically designed to address challenges in applying CAR-T therapies to solid tumors.
The patent was granted to The Wistar Institute and exclusively licensed to Anixa Biosciences. The company's CAR-T technology is currently being tested in a clinical trial at Moffitt Cancer Center for treating recurrent ovarian cancer patients.
Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the USPTO for a new patent covering its breast cancer vaccine technology. The patent, exclusively licensed from Cleveland Clinic, expands the scope of immunogenic compositions in Anixa's breast cancer vaccine development.
The newly allowed patent specifically covers methods of immunizing patients against breast cancer through the administration of an immunogenic composition containing the human α-lactalbumin protein. This protein is typically expressed during lactation in breast tissue and in certain breast cancers, making it a strategic target for immunoprevention approaches.
Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced its participation in the upcoming Jones Las Vegas Healthcare and Technology Innovation Conference. The event will take place on April 8-9, 2025, at The Venetian Resort in Las Vegas.
Mike Catelani, President and CFO of Anixa, is scheduled to present on April 9, 2025, at 4:30 PM PT. The presentation will be accessible via webcast, and Catelani will be available for one-on-one meetings throughout the conference.
The two-day conference, organized by Jones with B2i Digital's marketing support, will facilitate direct interactions between company executives and institutional investors through various formats including one-on-one meetings, fireside chats, panels, presentations, and networking events.
Anixa Biosciences (NASDAQ: ANIX) has entered into a letter of intent with VERDI Solutions to develop AI-guided personalized and off-the-shelf peptide vaccines for cancer patients. VERDI's cloud-computing platform enables rapid development of personalized vaccines tailored to individual cancer patients.
The agreement grants Anixa a six-month exclusive right to negotiate the research, development, and commercialization of VERDI's cancer vaccines. VERDI has already demonstrated success in three patients with bone metastases under Europe's Individueller Heilversuch program, where patients experienced clinical benefits including significant pain relief and improved quality of life.
VERDI's proprietary algorithm predicts vaccine efficacy in recognizing and eliminating tumor cells at an individual level. While VERDI continues developing personalized vaccines in Europe, both companies plan to initiate clinical trials in the United States.